25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

532649 (Nectar Lifesciences Limited) Stock Analysis
Buy, Hold or Sell?

Let's analyze Nectar Lifesciences Limited together

I guess you are interested in Nectar Lifesciences Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Nectar Lifesciences Limited’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Nectar Lifesciences Limited’s Price Targets

I'm going to help you getting a better view of Nectar Lifesciences Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Nectar Lifesciences Limited

I send you an email if I find something interesting about Nectar Lifesciences Limited.

1. Quick Overview

1.1. Quick analysis of Nectar Lifesciences Limited (30 sec.)










1.2. What can you expect buying and holding a share of Nectar Lifesciences Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
INR47.47
Expected worth in 1 year
INR43.31
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
INR-4.16
Return On Investment
-18.2%

For what price can you sell your share?

Current Price per Share
INR22.81
Expected price per share
INR20.05 - INR28.27
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Nectar Lifesciences Limited (5 min.)




Live pricePrice per Share (EOD)
INR22.81
Intrinsic Value Per Share
INR-51.64 - INR73.90
Total Value Per Share
INR-4.17 - INR121.37

2.2. Growth of Nectar Lifesciences Limited (5 min.)




Is Nectar Lifesciences Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$124.5m$127.2m-$2.7m-2.2%

How much money is Nectar Lifesciences Limited making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m$2.9m-$5.7m-203.6%
Net Profit Margin-1.6%1.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Nectar Lifesciences Limited (5 min.)




2.4. Comparing to competitors in the Drug Manufacturers - Major industry (5 min.)




  Industry Rankings (Drug Manufacturers - Major)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Nectar Lifesciences Limited?

Welcome investor! Nectar Lifesciences Limited's management wants to use your money to grow the business. In return you get a share of Nectar Lifesciences Limited.

First you should know what it really means to hold a share of Nectar Lifesciences Limited. And how you can make/lose money.

Speculation

The Price per Share of Nectar Lifesciences Limited is INR22.81. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nectar Lifesciences Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nectar Lifesciences Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR47.47. Based on the TTM, the Book Value Change Per Share is INR-1.04 per quarter. Based on the YOY, the Book Value Change Per Share is INR1.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nectar Lifesciences Limited.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps-0.01-0.1%-0.01-0.1%0.010.1%-0.01-0.1%0.000.0%0.020.1%
Usd Book Value Change Per Share-0.01-0.1%-0.01-0.1%0.010.1%-0.01-0.1%0.000.0%0.060.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.1%-0.01-0.1%0.010.1%-0.01-0.1%0.000.0%0.060.2%
Usd Price Per Share0.19-0.19-0.28-0.23-0.20-0.29-
Price to Earnings Ratio-14.71--14.71-21.53-0.38-3.23-7.87-
Price-to-Total Gains Ratio-15.26--15.26-20.05--0.31-2.79-1.92-
Price to Book Ratio0.33-0.33-0.50-0.41-0.35-0.55-
Price-to-Total Gains Ratio-15.26--15.26-20.05--0.31-2.79-1.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.266877
Number of shares3747
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (3747 shares)-45.574.22
Gains per Year (3747 shares)-182.2716.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-182-192897
20-365-374151924
30-547-556232841
40-729-738303758
50-911-920384675
60-1094-1102465692
70-1276-12845365109
80-1458-14666174126
90-1640-16486884143
100-1823-18307693160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%8.02.00.080.0%8.02.00.080.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%7.03.00.070.0%7.03.00.070.0%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%9.00.01.090.0%9.00.01.090.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%7.03.00.070.0%7.03.00.070.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Nectar Lifesciences Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.039-1.0390%1.154-190%-1.063+2%0.053-2064%4.747-122%
Book Value Per Share--47.47147.4710%48.511-2%47.780-1%48.656-2%45.948+3%
Current Ratio--1.3821.3820%1.350+2%1.258+10%1.271+9%1.226+13%
Debt To Asset Ratio--0.5140.5140%0.545-6%0.538-5%0.555-7%0.586-12%
Debt To Equity Ratio--1.0561.0560%1.198-12%1.168-10%1.254-16%1.436-26%
Dividend Per Share----0%0.046-100%0.032-100%0.043-100%0.072-100%
Enterprise Value---7510710666.880-7510710666.8800%-7473393142.4000%-7943489786.027+6%-9669623036.800+29%-8977058072.000+20%
Eps---1.078-1.0780%1.117-197%-1.0760%0.062-1830%1.325-181%
Ev To Sales Ratio---0.493-0.4930%-0.448-9%-0.505+2%-0.495+0%-0.485-2%
Free Cash Flow Per Share--4.6194.6190%3.123+48%2.434+90%5.307-13%4.798-4%
Free Cash Flow To Equity Per Share---3.656-3.6560%-2.200-40%-1.928-47%-1.350-63%-1.005-73%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--73.895----------
Intrinsic Value_10Y_min---51.638----------
Intrinsic Value_1Y_max--5.772----------
Intrinsic Value_1Y_min--0.521----------
Intrinsic Value_3Y_max--18.587----------
Intrinsic Value_3Y_min---3.358----------
Intrinsic Value_5Y_max--32.903----------
Intrinsic Value_5Y_min---12.604----------
Market Cap5115393227.520+30%3556779333.1203556779333.1200%5393476857.600-34%4373836880.640-19%3834862963.200-7%5522426928.000-36%
Net Profit Margin---0.016-0.0160%0.015-206%-0.016+1%-0.004-78%0.015-206%
Operating Margin----0%-0%-0%0.031-100%0.070-100%
Operating Ratio--0.8650.8650%0.821+5%0.839+3%1.215-29%1.431-40%
Pb Ratio0.481+30%0.3340.3340%0.496-33%0.408-18%0.353-5%0.551-39%
Pe Ratio-21.153-44%-14.708-14.7080%21.533-168%0.377-3997%3.233-555%7.872-287%
Price Per Share22.810+30%15.86015.8600%24.050-34%19.503-19%17.100-7%24.625-36%
Price To Free Cash Flow Ratio4.938+30%3.4333.4330%7.701-55%-10.387+403%-5.658+265%2.202+56%
Price To Total Gains Ratio-21.945-44%-15.259-15.2590%20.048-176%-0.309-98%2.790-647%1.919-895%
Quick Ratio--0.3340.3340%0.462-28%0.378-11%0.382-13%0.403-17%
Return On Assets---0.011-0.0110%0.010-205%-0.010-6%0.000-97%0.011-197%
Return On Equity---0.023-0.0230%0.023-199%-0.023+1%0.000-4885%0.030-175%
Total Gains Per Share---1.039-1.0390%1.200-187%-1.031-1%0.096-1180%4.819-122%
Usd Book Value--124557615.000124557615.0000%127284885.000-2%125366670.000-1%127666094.400-2%120560590.800+3%
Usd Book Value Change Per Share---0.012-0.0120%0.013-190%-0.012+2%0.001-2064%0.056-122%
Usd Book Value Per Share--0.5550.5550%0.568-2%0.559-1%0.569-2%0.538+3%
Usd Dividend Per Share----0%0.001-100%0.000-100%0.001-100%0.001-100%
Usd Enterprise Value---87875314.802-87875314.8020%-87438699.7660%-92938830.497+6%-113134589.531+29%-105031579.442+20%
Usd Eps---0.013-0.0130%0.013-197%-0.0130%0.001-1830%0.016-181%
Usd Free Cash Flow--12120147.00012120147.0000%8194095.000+48%6386796.000+90%13924474.200-13%12590370.000-4%
Usd Free Cash Flow Per Share--0.0540.0540%0.037+48%0.028+90%0.062-13%0.056-4%
Usd Free Cash Flow To Equity Per Share---0.043-0.0430%-0.026-40%-0.023-47%-0.016-63%-0.012-73%
Usd Market Cap59850100.762+30%41614318.19841614318.1980%63103679.234-34%51173891.503-19%44867896.669-7%64612395.058-36%
Usd Price Per Share0.267+30%0.1860.1860%0.281-34%0.228-19%0.200-7%0.288-36%
Usd Profit---2829411.000-2829411.0000%2930382.000-197%-2823600.0000%163542.600-1830%3477111.300-181%
Usd Revenue--178269273.000178269273.0000%195253344.000-9%184737930.000-4%231335067.600-23%217681857.900-18%
Usd Total Gains Per Share---0.012-0.0120%0.014-187%-0.012-1%0.001-1180%0.056-122%
 EOD+4 -4MRQTTM+0 -0YOY+10 -273Y+16 -215Y+10 -2810Y+12 -26

3.3 Fundamental Score

Let's check the fundamental score of Nectar Lifesciences Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-21.153
Price to Book Ratio (EOD)Between0-10.481
Net Profit Margin (MRQ)Greater than0-0.016
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.334
Current Ratio (MRQ)Greater than11.382
Debt to Asset Ratio (MRQ)Less than10.514
Debt to Equity Ratio (MRQ)Less than11.056
Return on Equity (MRQ)Greater than0.15-0.023
Return on Assets (MRQ)Greater than0.05-0.011
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Nectar Lifesciences Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.305
Ma 20Greater thanMa 5022.709
Ma 50Greater thanMa 10023.236
Ma 100Greater thanMa 20025.075
OpenGreater thanClose22.900
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Nectar Lifesciences Limited

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; and empty hard gelatin capsules. Further, the company menthol crystals, menthol powders and flakes, peppermint oils, dementholized peppermint oils, and menthone; CIS-3 hexenol, CIS-3-hexenol acetate/leaf acetate, and CIS-3-hexenol butyrate; mentha piperita oils, spearmint oils, distilled mentha oils/commint oils, distilled menthofuran, limonene, 3-octanol, terpenes, alpha pinene, beta pinene, 1.8 cineol, and ISO menthol; and menthone glycerol ketal, menthyl acetate, menthyl lactate, terpineol BP/USP/perfumery, pine oils, terpinolene, terpinen 4 ol, terpinyl acetate, lavendor ketone (3-Octanone), 3 menthyl cyclohexenone, and gamma terpinene. Nectar Lifesciences Limited was founded in 1995 and is headquartered in New Delhi, India.

Fundamental data was last updated by Penke on 2025-06-24 21:43:46.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Nectar Lifesciences Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compareΒ Nectar Lifesciences Limited to theΒ Drug Manufacturers - Major industry mean.
  • A Net Profit Margin of -1.6%Β means thatΒ ₹-0.02 for each ₹1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nectar Lifesciences Limited:

  • The MRQ is -1.6%. The company is making a loss. -1
  • The TTM is -1.6%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-1.6%TTM-1.6%0.0%
TTM-1.6%YOY1.5%-3.1%
TTM-1.6%5Y-0.4%-1.2%
5Y-0.4%10Y1.5%-1.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Nectar Lifesciences Limited is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Nectar Lifesciences Limited to theΒ Drug Manufacturers - Major industry mean.
  • -1.1% Return on Assets means thatΒ Nectar Lifesciences Limited generatedΒ ₹-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nectar Lifesciences Limited:

  • The MRQ is -1.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.1%TTM-1.1%0.0%
TTM-1.1%YOY1.0%-2.2%
TTM-1.1%5Y0.0%-1.1%
5Y0.0%10Y1.1%-1.2%
4.3.1.3. Return on Equity

Shows how efficient Nectar Lifesciences Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Nectar Lifesciences Limited to theΒ Drug Manufacturers - Major industry mean.
  • -2.3% Return on Equity means Nectar Lifesciences Limited generated ₹-0.02Β for eachΒ ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nectar Lifesciences Limited:

  • The MRQ is -2.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.3%TTM-2.3%0.0%
TTM-2.3%YOY2.3%-4.6%
TTM-2.3%5Y0.0%-2.3%
5Y0.0%10Y3.0%-3.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Nectar Lifesciences Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Nectar Lifesciences Limited is operatingΒ .

  • Measures how much profit Nectar Lifesciences Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Nectar Lifesciences Limited to theΒ Drug Manufacturers - Major industry mean.
  • An Operating Margin of 0.0%Β means the company generated ₹0.00 Β for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nectar Lifesciences Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y3.1%-3.1%
5Y3.1%10Y7.0%-3.9%
4.3.2.2. Operating Ratio

Measures how efficient Nectar Lifesciences Limited is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Major industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are ₹0.86 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 0.865. The company is less efficient in keeping operating costs low.
  • The TTM is 0.865. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.865TTM0.8650.000
TTM0.865YOY0.821+0.044
TTM0.8655Y1.215-0.350
5Y1.21510Y1.431-0.216
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Nectar Lifesciences Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Nectar Lifesciences Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Major industry mean).
  • A Current Ratio of 1.38Β means the company has ₹1.38 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 1.382. The company is just able to pay all its short-term debts.
  • The TTM is 1.382. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.382TTM1.3820.000
TTM1.382YOY1.350+0.032
TTM1.3825Y1.271+0.111
5Y1.27110Y1.226+0.045
4.4.3.2. Quick Ratio

Measures if Nectar Lifesciences Limited is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Nectar Lifesciences Limited to theΒ Drug Manufacturers - Major industry mean.
  • A Quick Ratio of 0.33Β means the company can pay off ₹0.33 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 0.334. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.334. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.334TTM0.3340.000
TTM0.334YOY0.462-0.128
TTM0.3345Y0.382-0.048
5Y0.38210Y0.403-0.021
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Nectar Lifesciences Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Nectar Lifesciences LimitedΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Nectar Lifesciences Limited to Drug Manufacturers - Major industry mean.
  • A Debt to Asset Ratio of 0.51Β means that Nectar Lifesciences Limited assets areΒ financed with 51.4% credit (debt) and the remaining percentage (100% - 51.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 0.514. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.514. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.514TTM0.5140.000
TTM0.514YOY0.545-0.031
TTM0.5145Y0.555-0.041
5Y0.55510Y0.586-0.032
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Nectar Lifesciences Limited is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Nectar Lifesciences Limited to theΒ Drug Manufacturers - Major industry mean.
  • A Debt to Equity ratio of 105.6% means that company has ₹1.06 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nectar Lifesciences Limited:

  • The MRQ is 1.056. The company is able to pay all its debts with equity. +1
  • The TTM is 1.056. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.056TTM1.0560.000
TTM1.056YOY1.198-0.141
TTM1.0565Y1.254-0.197
5Y1.25410Y1.436-0.182
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every ₹1 in earnings Nectar Lifesciences Limited generates.

  • Above 15 is considered overpriced butΒ always compareΒ Nectar Lifesciences Limited to theΒ Drug Manufacturers - Major industry mean.
  • A PE ratio of -14.71 means the investor is paying ₹-14.71Β for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nectar Lifesciences Limited:

  • The EOD is -21.153. Based on the earnings, the company is expensive. -2
  • The MRQ is -14.708. Based on the earnings, the company is expensive. -2
  • The TTM is -14.708. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-21.153MRQ-14.708-6.445
MRQ-14.708TTM-14.7080.000
TTM-14.708YOY21.533-36.241
TTM-14.7085Y3.233-17.941
5Y3.23310Y7.872-4.639
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nectar Lifesciences Limited:

  • The EOD is 4.938. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 3.433. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 3.433. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.938MRQ3.433+1.505
MRQ3.433TTM3.4330.000
TTM3.433YOY7.701-4.268
TTM3.4335Y-5.658+9.092
5Y-5.65810Y2.202-7.860
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Nectar Lifesciences Limited is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Major industry mean).
  • A PB ratio of 0.33 means the investor is paying ₹0.33Β for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Nectar Lifesciences Limited:

  • The EOD is 0.481. Based on the equity, the company is cheap. +2
  • The MRQ is 0.334. Based on the equity, the company is cheap. +2
  • The TTM is 0.334. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.481MRQ0.334+0.146
MRQ0.334TTM0.3340.000
TTM0.334YOY0.496-0.162
TTM0.3345Y0.353-0.019
5Y0.35310Y0.551-0.198
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
Operating Income  2,011,390-421,6501,589,740-1,342,980246,760768,9601,015,720-1,067,700-51,980



6.2. Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets21,892,110
Total Liabilities11,246,160
Total Stockholder Equity10,645,950
 As reported
Total Liabilities 11,246,160
Total Stockholder Equity+ 10,645,950
Total Assets = 21,892,110

Assets

Total Assets21,892,110
Total Current Assets12,311,830
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 175,520
Short-term Investments 3,140
Net Receivables 2,796,070
Inventory 7,315,150
Other Current Assets 368,250
Total Current Assets  (as reported)12,311,830
Total Current Assets  (calculated)10,658,130
+/- 1,653,700
Long-term Assets
Property Plant Equipment 6,904,280
Intangible Assets 493,290
Long-term Assets  (as reported)0
Long-term Assets  (calculated)7,397,570
+/- 7,397,570

Liabilities & Shareholders' Equity

Total Current Liabilities8,909,270
Long-term Liabilities0
Total Stockholder Equity10,645,950
Total Current Liabilities
Short-term Debt 4,589,130
Total Current Liabilities  (as reported)8,909,270
Total Current Liabilities  (calculated)4,589,130
+/- 4,320,140
Long-term Liabilities
Long term Debt Total 2,264,720
Long term Debt 2,261,630
Capital Lease Obligations Min Short Term Debt-4,589,130
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)-62,780
+/- 62,780
Total Stockholder Equity
Common Stock224,260
Retained Earnings 7,090,680
Capital Surplus 3,287,980
Other Stockholders Equity 43,030
Total Stockholder Equity (as reported)10,645,950
Total Stockholder Equity (calculated)10,645,950
+/-0
Other
Cash And Equivalents10
Cash and Short Term Investments 178,670
Common Stock Shares Outstanding 224,261
Liabilities and Stockholders Equity 21,892,110
Net Working Capital 3,402,560



6.3. Balance Sheets Structured

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
23,940,660
24,296,880
25,563,320
25,809,110
27,238,200
27,049,880
26,333,080
23,881,140
23,908,320
21,892,110
21,892,11023,908,32023,881,14026,333,08027,049,88027,238,20025,809,11025,563,32024,296,88023,940,660
   > Total Current Assets 
12,373,350
13,690,110
14,644,160
14,958,570
16,606,070
16,690,300
16,151,580
12,388,280
13,548,490
12,311,830
12,311,83013,548,49012,388,28016,151,58016,690,30016,606,07014,958,57014,644,16013,690,11012,373,350
       Cash And Cash Equivalents 
99,780
-10
-10
131,810
-10
212,890
212,935
238,650
157,790
175,520
175,520157,790238,650212,935212,890-10131,810-10-1099,780
       Short-term Investments 
3,140
4,350
5,230
4,080
5,100
5,060
1,660
4,570
4,600
3,140
3,1404,6004,5701,6605,0605,1004,0805,2304,3503,140
       Net Receivables 
4,564,620
4,464,960
4,914,470
4,997,300
6,119,700
5,587,320
3,958,720
3,748,260
4,469,780
2,796,070
2,796,0704,469,7803,748,2603,958,7205,587,3206,119,7004,997,3004,914,4704,464,9604,564,620
       Inventory 
7,584,270
8,493,600
8,889,690
9,108,820
9,175,080
9,733,700
10,080,850
6,553,220
7,212,600
7,315,150
7,315,1507,212,6006,553,22010,080,8509,733,7009,175,0809,108,8208,889,6908,493,6007,584,270
       Other Current Assets 
121,540
63,480
62,470
72,780
99,780
144,130
109,960
69,780
66,180
368,250
368,25066,18069,780109,960144,13099,78072,78062,47063,480121,540
   > Long-term Assets 
0
0
0
10,820,460
10,632,130
10,359,580
10,181,500
0
0
0
00010,181,50010,359,58010,632,13010,820,460000
       Property Plant Equipment 
10,698,070
10,250,430
9,369,360
9,259,110
9,062,170
8,851,860
8,606,550
8,321,530
7,651,750
6,904,280
6,904,2807,651,7508,321,5308,606,5508,851,8609,062,1709,259,1109,369,36010,250,43010,698,070
       Long Term Investments 
500
1,500
2,700
2,700
0
0
0
0
0
0
0000002,7002,7001,500500
       Intangible Assets 
0
797,560
679,950
574,430
459,240
391,820
391,910
383,640
430,210
493,290
493,290430,210383,640391,910391,820459,240574,430679,950797,5600
       Long-term Assets Other 
0
0
0
2,170
5,000
4,990
5,020
0
0
0
0005,0204,9905,0002,170000
> Total Liabilities 
14,670,040
15,276,590
16,022,510
15,742,350
16,651,600
15,998,270
14,971,830
13,260,840
13,029,270
11,246,160
11,246,16013,029,27013,260,84014,971,83015,998,27016,651,60015,742,35016,022,51015,276,59014,670,040
   > Total Current Liabilities 
11,260,660
11,562,610
12,399,490
12,786,590
13,093,210
12,999,050
12,478,910
11,873,920
10,038,330
8,909,270
8,909,27010,038,33011,873,92012,478,91012,999,05013,093,21012,786,59012,399,49011,562,61011,260,660
       Short-term Debt 
8,584,180
5,952,980
6,272,430
6,303,410
6,340,830
6,359,690
6,197,130
7,120,040
5,027,690
4,589,130
4,589,1305,027,6907,120,0406,197,1306,359,6906,340,8306,303,4106,272,4305,952,9808,584,180
       Short Long Term Debt 
8,584,180
9,247,770
9,621,100
8,781,050
7,349,780
7,378,610
6,572,820
0
0
0
0006,572,8207,378,6107,349,7808,781,0509,621,1009,247,7708,584,180
       Accounts payable 
4,400,610
4,555,770
4,967,810
5,280,980
5,394,240
4,836,740
5,271,450
0
0
0
0005,271,4504,836,7405,394,2405,280,9804,967,8104,555,7704,400,610
       Other Current Liabilities 
465,200
333,900
112,480
187,200
230,280
664,480
529,430
0
0
0
000529,430664,480230,280187,200112,480333,900465,200
   > Long-term Liabilities 
0
0
0
2,955,770
3,558,400
2,999,200
2,492,930
0
0
0
0002,492,9302,999,2003,558,4002,955,770000
       Long term Debt Total 
0
2,655,290
2,453,970
1,638,000
2,200,760
1,655,900
1,214,820
1,282,380
2,910,750
2,264,720
2,264,7202,910,7501,282,3801,214,8201,655,9002,200,7601,638,0002,453,9702,655,2900
       Capital Lease Obligations 
0
0
0
0
8,300
6,850
0
0
0
0
00006,8508,3000000
       Long-term Liabilities Other 
0
0
0
185,780
173,800
119,230
22,880
0
0
0
00022,880119,230173,800185,780000
       Deferred Long Term Liability 
80
359,120
0
0
0
0
0
0
0
0
00000000359,12080
> Total Stockholder Equity
9,270,620
9,020,290
9,540,810
10,066,760
10,586,600
11,051,610
11,361,250
10,620,300
10,879,050
10,645,950
10,645,95010,879,05010,620,30011,361,25011,051,61010,586,60010,066,7609,540,8109,020,2909,270,620
   Common Stock
224,260
224,260
224,260
224,260
224,260
224,260
224,260
224,260
224,260
224,260
224,260224,260224,260224,260224,260224,260224,260224,260224,260224,260
   Retained Earnings 
5,758,380
6,067,240
6,028,570
6,554,520
7,074,360
7,539,370
7,849,010
7,108,060
7,366,810
7,090,680
7,090,6807,366,8107,108,0607,849,0107,539,3707,074,3606,554,5206,028,5706,067,2405,758,380
   Capital Surplus 
0
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,980
3,287,9803,287,9803,287,9803,287,9803,287,9803,287,9803,287,9803,287,9803,287,9800
   Treasury Stock0000000000
   Other Stockholders Equity 
0
10
0
0
0
10,827,350
0
0
0
43,030
43,03000010,827,350000100



6.4. Balance Sheets

Currency in INR. All numbers in thousands.




6.5. Cash Flows

Currency in INR. All numbers in thousands.




6.6. Income Statements

Currency in INR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-03-31. Currency in INR. All numbers in thousands.

Gross Profit (+$)
totalRevenue15,236,690
Cost of Revenue-13,174,020
Gross Profit2,062,6702,062,670
 
Operating Income (+$)
Gross Profit2,062,670
Operating Expense-0
Operating Income-51,9802,062,670
 
Operating Expense (+$)
Research Development0
Selling General Administrative1,532,600
Selling And Marketing Expenses0
Operating Expense01,532,600
 
Net Interest Income (+$)
Interest Income809,670
Interest Expense-0
Other Finance Cost-809,670
Net Interest Income0
 
Pretax Income (+$)
Operating Income-51,980
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-424,200-51,980
EBIT - interestExpense = 0
-241,830
-241,830
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-424,200
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-424,200
Tax Provision--182,370
Net Income From Continuing Ops0-241,830
Net Income-241,830
Net Income Applicable To Common Shares-241,830
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net00
 

Technical Analysis of Nectar Lifesciences Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nectar Lifesciences Limited. The general trend of Nectar Lifesciences Limited is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nectar Lifesciences Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Nectar Lifesciences Limited Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nectar Lifesciences Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 23.06 < 25.53 < 28.27.

The bearish price targets are: 20.49 > 20.05.

Know someone who trades $532649? Share this with them.πŸ‘‡

Nectar Lifesciences Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nectar Lifesciences Limited. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nectar Lifesciences Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nectar Lifesciences Limited. The current macd is -0.45380073.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nectar Lifesciences Limited price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nectar Lifesciences Limited. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nectar Lifesciences Limited price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Nectar Lifesciences Limited Daily Moving Average Convergence/Divergence (MACD) ChartNectar Lifesciences Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nectar Lifesciences Limited. The current adx is 11.01.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Nectar Lifesciences Limited shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Nectar Lifesciences Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nectar Lifesciences Limited. The current sar is 20.70.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Nectar Lifesciences Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nectar Lifesciences Limited. The current rsi is 49.31. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Nectar Lifesciences Limited Daily Relative Strength Index (RSI) ChartNectar Lifesciences Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nectar Lifesciences Limited. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nectar Lifesciences Limited price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Nectar Lifesciences Limited Daily Stochastic Oscillator ChartNectar Lifesciences Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nectar Lifesciences Limited. The current cci is -9.30824155.

Nectar Lifesciences Limited Daily Commodity Channel Index (CCI) ChartNectar Lifesciences Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nectar Lifesciences Limited. The current cmo is 5.34894035.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Nectar Lifesciences Limited Daily Chande Momentum Oscillator (CMO) ChartNectar Lifesciences Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nectar Lifesciences Limited. The current willr is -33.9031339.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Nectar Lifesciences Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Nectar Lifesciences Limited Daily Williams %R ChartNectar Lifesciences Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Nectar Lifesciences Limited.

Nectar Lifesciences Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nectar Lifesciences Limited. The current atr is 1.1490025.

Nectar Lifesciences Limited Daily Average True Range (ATR) ChartNectar Lifesciences Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nectar Lifesciences Limited. The current obv is 7,948,588.

Nectar Lifesciences Limited Daily On-Balance Volume (OBV) ChartNectar Lifesciences Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nectar Lifesciences Limited. The current mfi is 36.39.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Nectar Lifesciences Limited Daily Money Flow Index (MFI) ChartNectar Lifesciences Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nectar Lifesciences Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-30MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Nectar Lifesciences Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nectar Lifesciences Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.305
Ma 20Greater thanMa 5022.709
Ma 50Greater thanMa 10023.236
Ma 100Greater thanMa 20025.075
OpenGreater thanClose22.900
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Nectar Lifesciences Limited with someone you think should read this too:
  • Are you bullish or bearish on Nectar Lifesciences Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nectar Lifesciences Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nectar Lifesciences Limited

I send you an email if I find something interesting about Nectar Lifesciences Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Nectar Lifesciences Limited.

Receive notifications about Nectar Lifesciences Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.